# Regulatory Agenda > Briefs, arguments, decisions, and more. URL: https://www.frixlaw.com/law-library/documents/fr%3A2023-14544 ## Record - **Collection:** Federal Register - **Document type:** Proposed Rule - **Published:** July 27, 2023 - **Citation:** 88 FR 48550 ## Text DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary 21 CFR Ch. I 25 CFR Ch. V 42 CFR Chs. I-V 45 CFR Subtitle A; Subtitle B, Chs. II, III, and XIII Regulatory Agenda AGENCY: Office of the Secretary, HHS. ACTION: Semiannual Regulatory Agenda. SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order (E.O.) 12866 require the semiannual issuance of an inventory of rulemaking actions under development throughout the Department, offering for public review summarized information about forthcoming regulatory actions. FOR FURTHER INFORMATION CONTACT: Elizabeth J. Gramling, Executive Secretary, Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201; (202) 690-5627. SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) is the Federal government's lead agency for protecting the health of all Americans and providing essential human services. HHS enhances the health and well-being of Americans by promoting effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services. This Agenda presents the regulatory activities that the Department expects to undertake in the foreseeable future to advance this mission. The purpose of the Agenda is to encourage more effective public participation in the regulatory process. The regulatory actions forecasted in this Agenda reflect the priorities of HHS Secretary Xavier Becerra and the Biden-Harris Administration. Accordingly, this Agenda contains rulemakings aimed at tackling the coronavirus disease 2019 (COVID-19) pandemic, building and expanding access to affordable, quality health care, addressing health disparities and promoting equity, and boosting the mental health and wellbeing of children and families, among other policy priorities. The rulemaking abstracts included in this paper issue of the Federal Register cover, as required by the Regulatory Flexibility Act of 1980, those prospective HHS rulemakings likely to have a significant economic impact on a substantial number of small entities. The Department's complete Regulatory Agenda is accessible online at http://www.RegInfo.gov. Elizabeth J. Gramling, HHS Executive Secretary. Office of the Secretary—Proposed Rule Stage Sequence No. Title Regulation Identifier No. 68 Limiting the Effect of Exclusions Implemented Under the Social Security Act (Rulemaking Resulting From a Section 610 Review) 0991-AC11 Substance Abuse and Mental Health Services Administration—Final Rule Stage Sequence No. Title Regulation Identifier No. 69 Medications for the Treatment of Opioid Use Disorder 0930-AA39 Centers for Disease Control and Prevention—Final Rule Stage Sequence No. Title Regulation Identifier No. 70 Control of Communicable Diseases; Foreign Quarantine 0920-AA75 Food and Drug Administration—Proposed Rule Stage Sequence No. Title Regulation Identifier No. 71 Medication Guide; Patient Medication Information 0910-AH68 72 Requirements for Tobacco Product Manufacturing Practice 0910-AH91 73 Administrative Detention of Tobacco Products 0910-AI05 74 Conduct of Analytical and Clinical Pharmacology, Bioavailability, and Bioequivalence Studies 0910-AI57 75 Amendments to the Final Rule Regarding the List of Bulk Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review) 0910-AI70 76 Distribution of Compounded Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review) 0910-AI71 77 Tobacco Product Standard for Nicotine Level of Certain Tobacco Products 0910-AI76 78 Registration of Commercial Importers of Drugs; Good Importing Practice 0910-AI87 Food and Drug Administration—Final Rule Stage Sequence No. Title Regulation Identifier No. 79 Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, Neutral Manner in Advertisements in Television and Radio Format 0910-AG27 80 Sunlamp Products; Amendment to the Performance Standard 0910-AG30 81 General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products 0910-AH14 82 Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act 0910-AH81 83 Nutrient Content Claims, Definition of Term: Healthy 0910-AI13 84 Revocation of Uses of Partially Hydrogenated Oils in Foods 0910-AI15 85 Tobacco Product Standard for Characterizing Flavors in Cigars 0910-AI28 86 Tobacco Product Standard for Menthol in Cigarettes 0910-AI60 Food and Drug Administration—Long-Term Actions Sequence No. Title Regulation Identifier No. 87 National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers 0910-AH11 88 Nicotine Toxicity Warnings 0910-AH24 89 Certain Requirements Regarding Prescription Drug Marketing (203 Amendment) 0910-AH56 90 Postmarketing Safety Reporting Requirements, Pharmacovigilance Plans, and Pharmacovigilance Quality Systems for Human Drug and Biological Products 0910-AI61 Food and Drug Administration—Completed Actions Sequence No. Title Regulation Identifier No. 91 Mammography Quality Standards Act 0910-AH04 Centers for Medicare & Medicaid Services—Proposed Rule Stage Sequence No. Title Regulation Identifier No. 92 FY 2024 Skilled Nursing Facility (SNFs) Prospective Payment System and Consolidated Billing and Updates to the Value-Based Purchasing and Quality Reporting Programs (CMS-1779) (Section 610 Review) 0938-AV02 93 CY 2024 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1784) (Section 610 Review) 0938-AV07 94 Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital Prospective Payment System; and FY 2024 Rates (CMS-1785) (Section 610 Review) 0938-AV08 95 CY 2024 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1786) (Section 610 Review) 0938-AV09 Centers for Medicare & Medicaid Services—Final Rule Stage Sequence No. Title Regulation Identifier No. 96 FY 2024 Hospice Wage Index, Payment Rate Update, and Quality Reporting Requirements (CMS-1787) (Section 610 Review) 0938-AV10 Centers for Medicare & Medicaid Services—Long-Term Actions Sequence No. Title Regulation Identifier No. 97 Medicare Advantage and Medicare Prescription Drug Benefit Program Payment Policy (CMS-4198) 0938-AU59 98 Omnibus COVID-19 Health Care Staff Vaccination (CMS-3415) (Section 610 Review) 0938-AU75 Administration for Children and Families—Proposed Rule Stage Sequence No. Title Regulation Identifier No. 99 Supporting the Head Start Workforce and Other Quality Improvements 0970-AD01 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Office of the Secretary (OS) Proposed Rule Stage 68. Limiting the Effect of Exclusions Implemented Under the Social Security Act (Rulemaking Resulting From a Section 610 Review) [0991-AC11] Legal Authority: 5 U.S.C. 301; 31 U.S.C. 6101 Abstract: HHS proposes to remove the regulatory provisions at issue, in order to align the regulation with the intent of the Social Security Act and current practice. Exclusions implemented under the Social Security Act prevent individuals convicted of certain crimes or individuals whose health care licenses have been revoked from participating in federal healthcare programs. Instead of only being barred from participating in all federal healthcare programs, certain regulatory provisions have resulted in these type of exclusion actions being given an overly broad government-wide effect, and excluded parties have been barred from participating in all Federal procurement and non-procurement actions. However, because Social Security Act exclusions are not issued under an agency's suspension and debarment authority, they do not stop individuals from participating in all federal procurement and non-procurement actions. For an agency to bar individuals from participating in all procurement and non-procurement activities, it must exercise its suspension and debarment authority under the Federal Acquisition Regulation or the Nonprocurement Common Rule. Timetable: Action Date FR Cite NPRM 06/00/23 Regulatory Flexibility Analysis Required: No. Agency Contact: Tiffani Redding, Program Analyst, Department of Health and Human Services, Office of the Secretary, 200 Independence Avenue SW, Washington, DC 20201, Phone: 202 768-0628, Email: tiffani.redding@hhs.gov . RIN: 0991-AC11 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) Final Rule Stage 69. Medications for the Treatment of Opioid Use Disorder [0930-AA39] Legal Authority: 21 U.S.C. 823(g)(1) Abstract: The Substance Abuse and Mental Health Services Administration (SAMHSA) will revise 42 CFR part 8 to make permanent some regulatory flexibilities for Opioid Treatment Programs (OTPs) granted under the COVID-19 Public Health Emergency (PHE), and to expand access to care for people with Opioid Use Disorder (OUD). Specifically, SAMHSA will propose making permanent those flexibilities pertaining to unsupervised doses of methadone and also initiation of buprenorphine via telemedicine. To expand access to care, SAMHSA will also review admission criteria, particularly rules that may limit timely access to treatment in an OTP. To achieve this, sections of 42 CFR part 8 will require updating. SAMHSA's changes will impact roughly 1900 opioid treatment programs and state opioid treatment authorities. In response to the Consolidated Appropriations Act of 2023, which removed the requirement to obtain a waiver in order to prescribe certain schedule III-V medications for the treatment of OUD, SAMHSA issued a supplemental notice of proposed rulemaking on Feb. 13, 2023, (88 FR 9221) calling for additional public comment on SAMHSA's plans to remove reference to the Drug Addiction Treatment Act of 2000 ( DATA 2000-Waiver) from 42 CFR part 8. Timetable: Action Date FR Cite NPRM 12/16/22 87 FR 77330 Supplemental NPRM 02/13/23 88 FR 9221 NPRM Comment Period End 02/14/23 Supplemental NPRM Comment Period End 03/14/23 Final Action 01/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Dr. Neeraj Gandotra, Chief Medical Officer, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, 18E67, Rockville, MD 20857, Phone: 202 823-1816, Email: neeraj.gandotra@samhsa.hhs.gov . RIN: 0930-AA39 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Disease Control and Prevention (CDC) Final Rule Stage 70. Control of Communicable Diseases; Foreign Quarantine [0920-AA75] Legal Authority: 42 U.S.C. 264; 42 U.S.C. 265 Abstract: This rulemaking amends current regulation to enable CDC to require airlines to collect and provide to CDC certain data elements regarding passengers and crew arriving from foreign countries under certain circumstances. Timetable: Action Date FR Cite Interim Final Rule Effective 02/07/20 Interim Final Rule 02/12/20 85 FR 7874 Interim Final Rule Comment Period End 03/13/20 Final Action 05/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Ashley C. Altenburger JD, Regulatory Analyst, Department of Health and Human Services, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS: H 16-4, Atlanta, GA 30307, Phone: 800 232-4636, Email: dgmqpolicyoffice@cdc.gov . RIN: 0920-AA75 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Proposed Rule Stage 71. Medication Guide; Patient Medication Information [0910-AH68] Legal Authority: 21 U.S.C. 321 et seq.; 42 U.S.C. 262; 42 U.S.C. 264; 21 U.S.C. 371 Abstract: The proposed rule would amend FDA medication guide regulations to require a new form of patient labeling, namely Patient Medication Information, for submission to and review by FDA for human prescription drug products and certain blood products used, dispensed, or administered on an outpatient basis. The proposed rule would include requirements for the development and distribution of Patient Medication Information. The proposed rule would require clear and concisely written prescription drug product information presented in a consistent and easily understood format to help patients use their prescription drug products safely and effectively. Timetable: Action Date FR Cite NPRM 05/31/23 88 FR 35694 NPRM Comment Period End 11/27/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Chris Wheeler, Supervisory Project Manager, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 3330, Silver Spring, MD 20993, Phone: 301 796-0151, Email: chris.wheeler@fda.hhs.gov . RIN: 0910-AH68 72. Requirements for Tobacco Product Manufacturing Practice [0910-AH91] Legal Authority: 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 381(a); 21 U.S.C. 387b; 21 U.S.C. 387c; 21 U.S.C. 387f; 21 U.S.C. 387i; . . . Abstract: The rule is proposing to establish tobacco product manufacturing practice (TPMP) requirements for manufacturers of finished and bulk tobacco products. This proposed rule, if finalized, would set forth requirements for the manufacture, pre-production design validation, packing, and storage of a tobacco product. This proposal would help prevent the manufacture and distribution of contaminated and otherwise nonconforming tobacco products. This proposed rule provides manufacturers with flexibility in the manner in which they comply with the proposed requirements while giving FDA the ability to enforce regulatory requirements, thus helping to assure the protection of public health. Timetable: Action Date FR Cite NPRM 03/10/23 88 FR 15174 NPRM Comment Period End 09/06/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Matthew Brenner, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov . RIN: 0910-AH91 73. Administrative Detention of Tobacco Products [0910-AI05] Legal Authority: 21 U.S.C. 334; 21 U.S.C. 371 Abstract: FDA is proposing a regulation to establish requirements for the administrative detention of tobacco products. This proposed rule, when finalized, would allow FDA to administratively detain tobacco products encountered during inspections of manufacturers or other establishments that manufacture, process, pack, or hold tobacco products that an authorized FDA representative conducting the inspection has reason to believe are adulterated or misbranded. The intent of administrative detention is to protect public health by preventing the distribution or use of tobacco products encountered during inspections that are believed to be adulterated or misbranded until FDA has had time to consider the appropriate action to take and, where appropriate, to initiate legal action. Timetable: Action Date FR Cite NPRM 02/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Quynh Nguyen, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov . Laura Chilaka, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov . RIN: 0910-AI05 74. Conduct of Analytical and Clinical Pharmacology, Bioavailability, and Bioequivalence Studies [0910-AI57] Legal Authority: 21 U.S.C. 355; 21 U.S.C. 371; 21 U.S.C. 374; 42 U.S.C. 262 Abstract: FDA is proposing to amend 21 CFR 320, in certain parts, and establish a new 21 CFR 321 to clarify FDA's study conduct expectations for clinical pharmacology, and clinical and analytical bioavailability (BA) and bioequivalence (BE) studies that support marketing applications for human drug and biological products. The proposed rule would specify needed basic study conduct requirements to enable FDA to ensure those studies are conducted appropriately and to verify the reliability of study data from those studies. This regulation would align with FDA's other good practice regulations, would also be consistent with current industry best practices, and would harmonize the regulations more closely with related international regulatory expectations. Timetable: Action Date FR Cite NPRM 04/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Brian Joseph Folian, Supervisory Biologist, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 5215, Silver Spring, MD 20993-0002, Phone: 240 402-4089, Email: brian.folian@fda.hhs.gov . RIN: 0910-AI57 75. Amendments to the Final Rule Regarding the List of Bulk Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review) [0910-AI70] Legal Authority: 21 U.S.C. 353a; 21 U.S.C. 351; 21 U.S.C. 371(a); 21 U.S.C. 352; 21 U.S.C. 355 Abstract: FDA has issued a regulation creating a list of bulk drug substances (active pharmaceutical ingredients) that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act, although they are neither the subject of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph nor components of FDA-approved drug products (the 503A Bulks List). The proposed rule will identify certain bulk drug substances that FDA has considered and is proposing to place on the 503A Bulks List and certain bulk drug substances that FDA has considered and is proposing not to include on the 503A Bulks List. Timetable: Action Date FR Cite NPRM 10/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Rosilend Lawson, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 5197, Silver Spring, MD 20993, Phone: 240 402-6223, Email: rosilend.lawson@fda.hhs.gov . RIN: 0910-AI70 76. Distribution of Compounded Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Section 610 Review) [0910-AI71] Legal Authority: 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 353a; 21 U.S.C. 353a-1; 21 U.S.C. 355; 21 U.S.C. 371 Abstract: The Food and Drug Administration is proposing rulemaking regarding statutory requirements under section 503A of the Federal Food, Drug, and Cosmetic Act for certain distributions of compounded human drug products. The proposed rule, if finalized, will include provisions regarding a standard memorandum of understanding (MOU) that describes the responsibilities of a State Board of Pharmacy or other appropriate State agency that chooses to sign the standard MOU in investigating complaints related to drug products compounded in such State and distributed outside such State and in addressing the interstate distribution of inordinate amounts of compounded human drug products. It will also, if finalized, include provisions regarding the statutory 5 percent limit on distribution of compounded human drug products out of the State in which they are compounded in States that do not sign the standard MOU. The rule, will also, if finalized, address communication with State boards of pharmacy. Timetable: Action Date FR Cite NPRM 10/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Dominic Markwordt, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Building 51, Room 5104, Silver Spring, MD 20993, Phone: 301 796-9349, Email: dominic.markwordt@fda.hhs.gov . RIN: 0910-AI71 77. Tobacco Product Standard for Nicotine Level of Certain Tobacco Products [0910-AI76] Legal Authority: 21 U.S.C. 387g Abstract: The proposed rule is a tobacco product standard that would establish a maximum nicotine level in cigarettes and certain other finished tobacco products. Timetable: Action Date FR Cite NPRM 12/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Courtney Smith, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, Document Control Center, Building 71, Room G335, 10903 New Hampshire Avenue, Silver Spring, MD 20993, Phone: 877 287-1373, Fax: 877 287-1426, Email: ctpregulations@fda.hhs.gov . RIN: 0910-AI76 78. • Registration of Commercial Importers of Drugs; Good Importing Practice [0910-AI87] Legal Authority: Sec. 714 of the Food and Drug Administrative Safety and Innovation Act (FDASIA) of July 2012 Abstract: This proposed rulemaking meets the mandate of section 714 of the Food and Drug Administration Safety and Innovation Act and will establish registration and good importing practice requirements for commercial importers of drugs. Although manufacturers are subject to regulatory requirements to ensure such quality standards are met, there are few clear responsibilities for commercial importers of drugs to do the same. Cost estimates of the rule include reading and understanding the rule, registering as a commercial importer through the Food and Drug Administration's (FDA) electronic importer registration system, annual updating of registration, establishing a quality management system, conducting risk evaluations of drugs and suppliers, shipment verifications, investigations, corrective actions, and records maintenance. The unquantified benefits of the proposed rule include improvement in the safety of finished drugs allowed to enter the United States from the commercial drug importer's requirement to register with FDA and for increased due diligence required by the importer regarding the safety of the drugs. There would also be cost savings to both FDA and industry from facilitating the review of documentation that ensures compliance with our regulations prior to being allowed to enter the United States. This proposed rulemaking will also enhance FDA's ability to collect and analyze data to enable risk-informed decision-making while focusing on protecting the integrity of the global drug supply chain and ensuring safety, effectiveness, and quality of imported drugs. Timetable: Action Date FR Cite NPRM 11/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: James Hanratty, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, WO 75, Rm. 1607A, 10903 New Hampshire Avenue, Silver Spring, MD 20993, Phone: 240 402-4718, Email: james.hanratty@fda.hhs.gov . RIN: 0910-AI87 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Final Rule Stage 79. Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, Neutral Manner in Advertisements in Television and Radio Format [0910-AG27] Legal Authority: 21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 352; 21 U.S.C. 355; 21 U.S.C. 360b; 21 U.S.C. 371; . . . Abstract: The Food and Drug Administration (FDA) is amending its regulations concerning direct-to-consumer (DTC) advertisements of prescription drugs. Prescription drug advertisements presented through media such as TV and radio must disclose the product's major side effects and contraindications in what is sometimes called the major statement. The rule would revise the regulation to reflect the statutory requirement that in DTC advertisements for human prescription drugs presented in television or radio format and stating the name of the drug and its conditions of use, the major statement relating to side effects and contraindications of the advertised drug must be presented in a clear, conspicuous, and neutral manner. This rule also establishes standards for determining whether the major statement in these advertisements is presented in the manner required. Timetable: Action Date FR Cite NPRM 03/29/10 75 FR 15376 NPRM Comment Period End 06/28/10 NPRM Comment Period Reopened 01/27/12 77 FR 4273 NPRM Comment Period End 02/27/12 NPRM Comment Period Reopened 03/29/12 77 FR 16973 NPRM Comment Period Reopened End 04/09/12 Final Rule 07/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Suzanna Boyle, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, WO 51, Room 3214, Silver Spring, MD 20993, Phone: 240 402-4723, Email: suzanna.boyle@fda.hhs.gov . RIN: 0910-AG27 80. Sunlamp Products; Amendment to the Performance Standard [0910-AG30] Legal Authority: 21 U.S.C. 360ii; 21 U.S.C. 360kk; 21 U.S.C. 393; 21 U.S.C. 371 Abstract: FDA is updating the performance standard for sunlamp products and ultraviolet lamps intended for use in these products to improve safety, reflect new scientific information, and work towards harmonization with international standards. By harmonizing with the International Electrotechnical Commission, this rule will decrease the regulatory burden on industry and allow the Agency to take advantage of the expertise of the international committees, thereby also saving resources. Timetable: Action Date FR Cite NPRM 12/22/15 80 FR 79505 NPRM Comment Period End 03/21/16 Final Rule 06/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Ian Ostermiller, Regulatory Counsel, Center for Devices and Radiological Health, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, WO 66, Room 5454, Silver Spring, MD 20993, Phone: 301 796-5678, Email: ian.ostermiller@fda.hhs.gov . RIN: 0910-AG30 81. General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products [0910-AH14] Legal Authority: 21 U.S.C. 360j(e) Abstract: This rule will apply device restrictions to sunlamp products. Sunlamp products include ultraviolet (UV) lamps and UV tanning beds and booths. The incidence of skin cancer, including melanoma, has been increasing, and a large number of skin cancer cases are attributable to the use of sunlamp products. The devices may cause about 400,000 cases of skin cancer per year, and 6,000 of which are melanoma. Beginning use of sunlamp products at young ages, as well as frequently using sunlamp products, both increases the risk of developing skin cancers and other illnesses, and sustaining other injuries. Even infrequent use, particularly at younger ages, can significantly increase these risks. Timetable: Action Date FR Cite NPRM 12/22/15 80 FR 79493 NPRM Comment Period End 03/21/16 Final Rule 12/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Daniel Schieffer, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, 10903 New Hampshire Avenue, WO 75, Room 7613, Silver Spring, MD 20993, Phone: 301 796-3350, Email: daniel.schieffer@fda.hhs.gov. RIN: 0910-AH14 82. Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act [0910-AH81] Legal Authority: 21 U.S.C. 351; 21 U.S.C. 352; 21 U.S.C. 353a; 21 U.S.C. 355; 21 U.S.C. 371 Abstract: FDA has issued a regulation creating a list of bulk drug substances (active pharmaceutical ingredients) that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), although they are neither the subject of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph nor components of FDA-approved drugs (the 503A Bulks List). FDA has proposed to amend the 503A Bulks List by placing additional bulk drug substances on the list. FDA has also identified bulk drug substances that FDA has considered and proposed not to include on the 503A Bulks List. Additional substances nominated by the public for inclusion on this list are currently under consideration and will be the subject of future rulemaking. Timetable: Action Date FR Cite NPRM 09/05/19 84 FR 46688 NPRM Comment Period End 12/04/19 Final Rule 10/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Rosilend Lawson, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 5197, Silver Spring, MD 20993, Phone: 240 402-6223, Email: rosilend.lawson@fda.hhs.gov. RIN: 0910-AH81 83. Nutrient Content Claims, Definition of Term: Healthy [0910-AI13] Legal Authority: 21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 343; 21 U.S.C. 371 Abstract: The proposed rule would update the definition for the implied nutrient content claim “healthy” to be consistent with current nutrition science and federal dietary guidelines. The proposed rule would revise the requirements for when the claim “healthy” can be voluntarily used in the labeling of human food products to indicate that a food, because of its nutrient content, may be useful in achieving a total diet that conforms to current dietary recommendations and helps consumers maintain healthy dietary practices. Timetable: Action Date FR Cite NPRM 09/29/22 87 FR 59168 NPRM Comment Period End 12/28/22 NPRM Comment Period Extended 11/29/22 87 FR 73267 NPRM Comment Period Extended End 02/16/23 Final Action 04/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Vincent De Jesus, Nutritionist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, (HFS-830), Room 3D-031, 5100 Paint Branch Parkway, College Park, MD 20740, Phone: 240 402-1774, Fax: 301 436-1191, Email: vincent.dejesus@fda.hhs.gov. RIN: 0910-AI13 84. Revocation of Uses of Partially Hydrogenated Oils in Foods [0910-AI15] Legal Authority: 21 U.S.C. 321; 21 U.S.C. 341; 21 U.S.C. 342; 21 U.S.C. 343; 21 U.S.C. 348; 21 U.S.C. 371; 21 U.S.C. 379e Abstract: In the Federal Register of June 17, 2015 (80 FR 34650), we published a declaratory order announcing our final determination that there is no longer a consensus among qualified experts that partially hydrogenated oils (PHOs) are generally recognized as safe (GRAS) for any use in human food. In the Federal Register of May 21, 2018 (83 FR 23382), we denied a food additive petition requesting that the food additive regulations be amended to provide for the safe use of PHOs in certain food applications. We are now planning to issue a direct final rule and companion proposed rule to update our regulations to remove all mention of partially hydrogenated oils from FDA's GRAS regulations and as an optional ingredient in standards of identity. We are also revoking all prior sanctions for uses of PHOs in food. Timetable: Action Date FR Cite Direct Final Rule 06/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Ellen Anderson, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, HFS-265, 4300 River Road, College Park, MD 20740, Phone: 240 402-1309, Email: ellen.anderson@fda.hhs.gov. RIN: 0910-AI15 85. Tobacco Product Standard for Characterizing Flavors in Cigars [0910-AI28] Legal Authority: 21 U.S.C. 331; 21 U.S.C. 333; 21 U.S.C. 371(a); 21 U.S.C. 387b and 387c; 21 U.S.C. 387f(d) and 387g; . . . Abstract: This rule is a tobacco product standard that would prohibit characterizing flavors (other than tobacco) in all cigars. We are taking this action with the intention of reducing the tobacco-related death and disease associated with cigar use. Evidence shows that flavored tobacco products appeal to youth and also shows that youth may be more likely to initiate tobacco use with such products. Characterizing flavors in cigars, such as strawberry, grape, orange, and cocoa, enhance taste and make these products easier to use. Over a half million youth in the United States use flavored cigars, placing these youth at risk for cigar-related death and disease. Timetable: Action Date FR Cite ANPRM 03/21/18 83 FR 12294 ANPRM Comment Period End 07/19/18 NPRM 05/04/22 87 FR 26396 NPRM Comment Period Extended 06/21/22 87 FR 36786 NPRM Comment Period End 07/05/22 NPRM Comment Period Extended End 08/02/22 Final Rule 08/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Nathan Mease, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Center for Tobacco Products, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov. RIN: 0910-AI28 86. Tobacco Product Standard for Menthol in Cigarettes [0910-AI60] Legal Authority: 21 U.S.C. 387g; 21 U.S.C 371; 21 U.S.C 387f Abstract: This final rule is a tobacco product standard to prohibit the use of menthol as a characterizing flavor in cigarettes. Timetable: Action Date FR Cite ANPRM 07/24/13 78 FR 44484 ANPRM Comment Period End 09/23/13 NPRM 05/04/22 87 FR 26454 NPRM Comment Period Extended 06/21/22 87 FR 36786 NPRM Comment Period End 07/05/22 NPRM Comment Period Extended End 08/02/22 Final Rule 08/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Beth Buckler, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov. RIN: 0910-AI60 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Long-Term Actions 87. National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers [0910-AH11] Legal Authority: Secs. 583 and 584 of the FD&C Act, as added by the DSCSA under Pub. L. 113-54, together with related FD&C Act authority added by the DSCSA Abstract: The final rule establishes national standards for State licensing of prescription drug wholesale distributors and third-party logistics providers. The rulemaking also establishes a Federal system for wholesale drug distributor and third-party logistics provider licensing for use in the absence of a State licensure program. Timetable: Action Date FR Cite NPRM 02/04/22 87 FR 6708 NPRM Comment Period End 06/06/22 NPRM Comment Period Extended 05/24/22 87 FR 31439 NPRM Comment Period Extended End 09/06/22 Final Rule 04/00/25 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Aaron Weisbuch, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Building 51, Room 4261, 10903 New Hampshire Avenue, Silver Spring, MD 20993, Phone: 301 796-9362, Email: aaron.weisbuch@fda.hhs.gov. RIN: 0910-AH11 88. Nicotine Toxicity Warnings [0910-AH24] Legal Authority: 21 U.S.C. 301 et seq.; 21 U.S.C. 331; 21 U.S.C. 371; 21 U.S.C. 387f; . . . Abstract: This rule would establish acute nicotine toxicity warning requirements for liquid nicotine and nicotine-containing e-liquid(s) intended for human consumption, and potentially for other tobacco products including, but not limited to, novel tobacco products such as dissolvables, lotions, gels, and drinks. This action is intended to increase consumer awareness and knowledge of the risks of acute toxicity due to accidental nicotine exposure from nicotine-containing e-liquids in tobacco products. Timetable: Action Date FR Cite NPRM 10/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Laura Chilaka, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G355, Silver Spring, MD 20993, Phone: 877 287-1373, Email: ctpregulations@fda.hhs.gov. RIN: 0910-AH24 89. Certain Requirements Regarding Prescription Drug Marketing (203 Amendment) [0910-AH56] Legal Authority: Section 503 and related provisions of the FD&C Act, as amended by Pub. L. 113-54 Abstract: The final rule amends Food and Drug Administration (FDA) regulations at 21 CFR 203 to remove provisions no longer in effect and incorporate conforming changes following enactment of the Drug Supply Chain Security Act (DSCSA). The final rule amends the regulations to clarify provisions and avoid causing confusion with the new standards for wholesale distribution established by DSCSA. Timetable: Action Date FR Cite NPRM 02/04/22 87 FR 6443 NPRM Comment Period End 04/05/22 Final Rule 04/00/25 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Aaron Weisbuch, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Building 51, Room 4261, 10903 New Hampshire Avenue, Silver Spring, MD 20993, Phone: 301 796-9362, Email: aaron.weisbuch@fda.hhs.gov. RIN: 0910-AH56 90. Postmarketing Safety Reporting Requirements, Pharmacovigilance Plans, and Pharmacovigilance Quality Systems for Human Drug and Biological Products [0910-AI61] Legal Authority: 42 U.S.C. 262; 42 U.S.C. 264; 42 U.S.C. 300aa-25; 21 U.S.C. 321; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371; 21 U.S.C. 374; . . . Abstract: The proposed rule would modernize FDA's regulations on postmarketing safety reporting and pharmacovigilance for human drug and biological products, including blood and blood components, by capturing important new safety-related information, improving the quality and utility of submitted reports, and supporting enhanced alignment with internationally harmonized reporting guidelines. Among other things, the proposed rule would require the submission of certain nonclinical and clinical data to FDA in a periodic safety report, rather than the annual report. The proposed rule also would require application holders for drug products and certain biological products to establish and maintain a pharmacovigilance quality system that reflects the application holder's unique needs and that may support a more streamlined, flexible approach to satisfying certain postmarketing safety reporting requirements. Timetable: Action Date FR Cite NPRM 05/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Janice L. Weiner, Principal Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Building 51, Room 6270, Silver Spring, MD 20993-0002, Phone: 301 796-3475, Fax: 301 847-8440, Email: janice.weiner@fda.hhs.gov. RIN: 0910-AI61 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Food and Drug Administration (FDA) Completed Actions 91. Mammography Quality Standards Act [0910-AH04] Legal Authority: 21 U.S.C. 360i; 21 U.S.C. 360nn; 21 U.S.C. 374(e); 42 U.S.C. 263b Abstract: FDA is amending its regulations governing mammography. The amendments will update the regulations issued under the Mammography Quality Standards Act of 1992 (MQSA) and the Federal Food, Drug, and Cosmetic Act (FD&C Act). FDA is taking this action to address changes in mammography technology and mammography processes that have occurred since the regulations were published in 1997 and to address breast density reporting to patient and healthcare providers. Completed: Reason Date FR Cite Final Rule 03/10/23 88 FR 15126 Final Action Effective 09/10/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Laurie Sternberg, Phone: 240 402-0425, Email: laurie.sternberg@fda.hhs.gov. RIN: 0910-AH04 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Proposed Rule Stage 92. FY 2024 Skilled Nursing Facility (SNFS) Prospective Payment System and Consolidated Billing and Updates to the Value-Based Purchasing and Quality Reporting Programs (CMS-1779) (Section 610 Review) [0938-AV02] Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302 Abstract: This annual final rule updates the payment rates used under the prospective payment system for SNFs for fiscal year 2024. The rule also includes changes for the SNF Quality Reporting Program (QRP) and for the Skilled Nursing Facility Value-Based Purchasing (VBP) Program that will affect Medicare payment to SNFs. Timetable: Action Date FR Cite NPRM 04/10/23 88 FR 21316 NPRM Comment Period End 06/05/23 Final Action 10/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Tammy Luo, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C5-06-17, 7500 Security Boulevard, Baltimore, MD 21244, Phone: 410 786-4325, Email: tammy.luo@cms.hhs.gov. RIN: 0938-AV02 93. CY 2024 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1784) (Section 610 Review) [0938-AV07] Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302 Abstract: This annual proposed rule would revise payment polices under the Medicare physician fee schedule, and make other policy changes to payment under Medicare Part B including, but not limited to, establishing payment policies for dental services prior to the initiation of immunotherapy services. These changes would apply to services furnished beginning January 1, 2024. Additionally, this rule proposes updates to the Quality Payment Program. Timetable: Action Date FR Cite NPRM 06/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Gift Tee, Director, Division of Physician Services, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, 7500 Security Boulevard, MS: C1-09-07, Baltimore, MD 21244, Phone: 410 786-9316, Email: gift.tee@cms.hhs.gov. RIN: 0938-AV07 94. Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital Prospective Payment System; and FY 2024 Rates (CMS-1785) (Section 610 Review) [0938-AV08] Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302 Abstract: This annual proposed rule would revise the Medicare hospital inpatient and long-term care hospital prospective payment systems for operating and capital-related costs. This proposed rule would implement changes arising from our continuing experience with these systems. In addition, the rule proposes to establish new requirements or revise existing requirements for quality reporting by specific Medicare providers. Timetable: Action Date FR Cite NPRM 06/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Donald Thompson, Director, Division of Acute Care, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-01-26, 7500 Security Boulevard, Baltimore, MD 21244, Phone: 410 786-6504, Email: donald.thompson@cms.hhs.gov. RIN: 0938-AV08 95. CY 2024 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1786) (Section 610 Review) [0938-AV09] Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302 Abstract: This annual proposed rule would revise the Medicare hospital outpatient prospective payment system to implement statutory requirements and changes arising from our continuing experience with this system. The proposed rule describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule proposes changes to the ambulatory surgical center payment system list of services and rates. This proposed rule would also update and refine the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. Timetable: Action Date FR Cite NPRM 06/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Elise Barringer, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-03-06, 7500 Security Boulevard, Baltimore, MD 21244, Phone: 410 786-9222, Email: elise.barringer@cms.hhs.gov. RIN: 0938-AV09 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Final Rule Stage 96. FY 2024 Hospice Wage Index, Payment Rate Update, and Quality Reporting Requirements (CMS-1787) (Section 610 Review) [0938-AV10] Legal Authority: 42 U.S.C. 1302; 42 U.S.C. 1395hh Abstract: This annual final rule updates the hospice payment rates and the wage index for fiscal year 2024. The rule also finalizes changes to the Hospice Quality Reporting program. Timetable: Action Date FR Cite NPRM 04/04/23 88 FR 20022 NPRM Comment Period End 05/30/23 Final Action 10/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Brian Slater, Director, Division of Home Health and Hospice, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-07-07, 7500 Security Boulevard, Baltimore, MD 21244, Phone: 410 786-5229, Email: brian.slater@cms.hhs.gov. RIN: 0938-AV10 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Medicare & Medicaid Services (CMS) Long-Term Actions 97. Medicare Advantage and Medicare Prescription Drug Benefit Program Payment Policy (CMS-4198) [0938-AU59] Legal Authority: 42 U.S.C. 1395w Abstract: This proposed rule would codify long-established Medicare Advantage and Part D payment policies that are outside the scope of the annual Advance Notice/Rate Announcement. Timetable: Action Date FR Cite NPRM 06/00/24 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Jennifer Shapiro, Director, Medicare Plan Payment Group, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C1-13-18, 7500 Security Boulevard, Baltimore, MD 21244, Phone: 410 786-7407, Email: jennifer.shapiro@cms.hhs.gov. RIN: 0938-AU59 98. Omnibus COVID-19 Health Care Staff Vaccination (CMS-3415) (Section 610 Review) [0938-AU75] Legal Authority: 42 U.S.C. 1395hh; 42 U.S.C. 1302 Abstract: This interim final rule with comment period revises the infection control requirements that most Medicare- and Medicaid-participating providers and suppliers must meet to participate in the Medicare and Medicaid programs. These changes are necessary to protect the health and safety of residents, clients, patients, and staff and reflect lessons learned as result of the COVID-19 public health emergency. The revisions to the infection control requirements establish COVID-19 vaccination requirements for staff at the included Medicare- and Medicaid-participating providers and suppliers. Timetable: Action Date FR Cite Interim Final Rule 11/05/21 86 FR 61555 Interim Final Rule Effective 11/05/21 Interim Final Rule Comment Period End 01/04/22 Reviewing Public Comments To Be Determined Regulatory Flexibility Analysis Required: Yes. Agency Contact: Lauren Oviatt, Acting Director, Division of Non-Institutional Standards and Quality, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, MS: C2-21-16, 7500 Security Boulevard, Baltimore, MD 21244-1850, Phone: 410 786-4683, Email: lauren.oviatt@cms.hhs.gov. RIN: 0938-AU75 DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Administration for Children and Families (ACF) Proposed Rule Stage 99. • Supporting the Head Start Workforce and Other Quality Improvements [0970-AD01] Legal Authority: 42 U.S.C. 9801; 42 U.S.C. 9836a; 42 U.S.C. 9839 Abstract: This NPRM will propose changes to the Head Start Program Performance Standards to better support the Head Start workforce and to maintain the quality of comprehensive Head Start services. Timetable: Action Date FR Cite NPRM 07/00/23 Regulatory Flexibility Analysis Required: Yes. Agency Contact: Lindsey A Hutchison, Senior Policy Analyst, Department of Health and Human Services, Administration for Children and Families, 330 C Street SW, #4305B, Washington, DC 20201, Phone: 904 860-7032, Email: lindsey.hutchison@acf.hhs.gov. RIN: 0970-AD01 [FR Doc. 2023-14544 Filed 7-26-23; 8:45 am] BILLING CODE 4150-03-P --- Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2023-14544. Public record. Not legal advice.